Dr Arance discusses the long-term survival rates for patients receiving current standard of care therapies, and the potential for some patients to achieve long-term control of their melanoma1/3 Next Interview
Prof. Ascieto highlights the factors that influence response to treatment and provides insights on the strategies that may optimize survival in patients who have a poor prognosis, including the use of treatment sequencing2/3 Next Interview
Dr Betof Warner reviews the evolving treatment landscape in melanoma to discuss the latest data on triplet combinations and novel therapies, and provides insights on how these may impact future directions in melanoma.3/3 Take CME Test
Overview & Learning Objectives
Watch leading experts discuss evolving neoadjuvant, adjuvant and metastatic treatment options for patients with melanoma, taking in the latest data presented at the ESMO Congress 2021.
This activity is jointly provided by USF Health and touchIME. read more
This activity has been designed to meet the educational needs of Oncologists, including dermato-oncologists and other HCPs involved in the management of patients with melanoma.
All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Dr Arance discloses: Advisory board/panel discussion fees from Bristol Myers Squibb, Merck/Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche and Sanofi Genzyme; consultancy fees from Bristol Myers Squibb, Merck/Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche and Sanofi Genzyme; grants and research support fees from Amgen, Bristol Myers Squibb, Merck/Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche and Sanofi Genzyme; speaker’s bureau fees from Bristol Myers Squibb, Merck/Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche and Sanofi Genzyme.
Prof. Ascieto discloses: Advisory board/panel discussion fees from 4SC, Alkermes, Array BioPharma, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eisai Co. Ltd., Genentech; Idera Pharmaceuticals, Immunocore, Incyte Corp., Italfarmaco SpA., iTeos Therapeutics, MedImmune, Merck Serono, Merck Sharp & Dohme, Nektar Therapeutics, Novartis, Oncosec Medical, Pfizer, Pierre Fabre, Regeneron, Sandoz, Sanofi Genzyme, Seagen, Sun Pharmaceutical Industries Ltd., Syndax Pharmaceuticals Inc. and Ultimovacs; consultancy fees from 4SC, Bristol Myers Squibb, Genentech, Italfarmaco SpA., Lunaphore Technologies SA, Merck Sharp & Dohme, Nouscom, Novartis, Pfizer, Sandoz, Sanofi Genzyme and Takis Biotech; grants and research support from Array BioPharma, Bristol Myers Squibb, Genentech and Sanofi Genzyme; travel support from Merck Sharp & Dohme.
Dr Allison Betof Warner discloses: Advisory board/panel discussion fees from Iovance Biotherapeutics; consultancy fees from Iovance Biotherapeutics, Novartis, Pfizer, and Novartis and Shanghai Jo’Ann Medical Technology (relationships terminated).
Angela Massey Hill, Pharm.D., CPh, RPh has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Kathy Day has no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact email@example.com
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu)
Advanced Practice Providers
Physician Assistants may claim a maximum of 1 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Date of original release: 12 October 2021. Date credit expire: 12 October 2022.
If you have any questions regarding credit please contact firstname.lastname@example.org
After watching this activity, participants should be better able to:
- Describe the long-term survival results in patients with melanoma and their relevance to treatment decisions
- Evaluate current strategies to improve outcomes for patients with melanoma who do not experience a durable response
- Recall the latest data for emerging treatment options, including the use of triple combination approaches, and how these therapies fit into the melanoma treatment paradigm